Diabeloop for Kids
Diabeloop for Kids
An open-label, three-center, randomized, two-session, 4 days inpatient and 6-week follow-up
 home study phase, crossover study comparing Diabeloop closed-loop (CL) system and
 sensor-augmented pump (SAP) therapy.

 The follow-up home study phase will be done only in French centers for a sub study. During
 this session, patient wearing the closed-loop system will benefit of a 24h/24, 7 d/7, remote
 monitoring follow-up by specialized nurses, under supervision of a diabetologist. A
 visualization of glucose CGM curves, insulin delivery, meal and physical activity
 announcements will be available online through secured website, and the system will send
 automated message in case of predetermined situations as persistent too high or too low Blood
 Glucose (BG). Custom settings will be possible by the nurses during the follow-up period.
Inclusion Criteria:

 -  Prepubescent children (Gender: both) aged between 6 to 12 years old (Tanner stage 1)
 at time of screening

 -  Type 1 diabetes as defined by WHO for at least 1 year or confirmed C peptide negative

 -  An insulin pump user for at least 3 months.

 -  Subject having a Glycosylated hemoglobin (HbA1c) blood value < 9% at time of screening
 visit-based on analysis from local laboratory within 3 months.

 -  Subject having a minimum daily insulin requirement (Total Daily Dose) of greater than
 or equal to 8 units.

 -  Subject and his parent/guardian willing to spend 3-overnight in hospital.

 -  Subject willing to wear the system continuously throughout the study

 -  Subjects and his parent/guardian must be able to speak and be literate in French or
 Flemish as verified by the investigator

 Exclusion Criteria:

 -  Children who are in pubertal stage

 -  Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in
 any the following during the 6 months prior to screening: - Medical assistance (i.e.
 Paramedics, Emergency Room (ER) or Hospitalization) - Coma - Seizures

 -  Subject having sever DKA in the 6 months prior to screening visit.

 -  Known or suspected allergy against insulin

 -  Any other physical or psychological disease, or medication likely to interfere with
 the conduct of the study and interpretation of the study results as judged by the
 investigator.

 -  Subject is unable to tolerate tape adhesive around the sensor or pump placements

 -  Subject has a cardiovascular condition which the investigator determines should
 exclude the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy

 -  Subject having took any oral, injectable, or intravenous (IV) glucocorticoids within 8
 weeks from time of screening visit, or plans to take any oral, injectable, or IV
 glucocorticoids during the study.